Michael T. Hemann, Ph.D. - Publications

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Telomeres and telomerase in chromosome maintenance and stability

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell. PMID 26924578 DOI: 10.1016/j.cell.2016.01.045  0.96
2016 Zhao B, Hemann MT, Lauffenburger DA. Modeling tumor clonal evolution for drug combinations design Trends in Cancer. 2: 144-158. DOI: 10.1016/j.trecan.2016.02.001  0.96
2015 Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cancer Cell. PMID 26602816 DOI: 10.1016/j.ccell.2015.09.009  0.96
2015 Shingleton JR, Hemann MT. The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies. Plos One. 10: e0143275. PMID 26588464 DOI: 10.1371/journal.pone.0143275  0.96
2015 McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Research. PMID 26025730 DOI: 10.1158/0008-5472.CAN-14-3616  0.96
2015 Hemann M. Chimeric tumor and organ transplantation models Cold Spring Harbor Protocols. 2015: 725-730. DOI: 10.1101/pdb.top06987  0.96
2015 Hemann M. Loss-of-function screening in hematopoietic malignancies Cold Spring Harbor Protocols. 2015: 740-742. DOI: 10.1101/pdb.prot078022  0.96
2015 Hemann M. Syngeneic transplants with modified chimeric hematopoietic tumors Cold Spring Harbor Protocols. 2015: 735-739. DOI: 10.1101/pdb.prot078014  0.96
2012 Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 15: 249-57. PMID 23164555 DOI: 10.1016/j.drup.2012.10.003  0.96
2012 Hemann MT. The development and use of genetically tractable preclinical mouse models Genetically Engineered Mice For Cancer Research: Design, Analysis, Pathways, Validation and Pre-Clinical Testing. 477-495. DOI: 10.1007/978-0-387-69805-2_23  0.96
2011 Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Research. 71: 5850-8. PMID 21784872 DOI: 10.1158/0008-5472.CAN-11-1014  0.96
2011 Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Research. 71: 5062-6. PMID 21771909 DOI: 10.1158/0008-5472.CAN-11-0277  0.96
2011 Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. Journal of Immunology (Baltimore, Md. : 1950). 187: 664-75. PMID 21690328 DOI: 10.4049/jimmunol.1100029  0.96
2011 Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nature Chemical Biology. 7: 92-100. PMID 21186347 DOI: 10.1038/nchembio.503  0.96
2010 Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 468: 572-5. PMID 21107428 DOI: 10.1038/nature09535  0.96
2010 Xie K, Doles J, Hemann MT, Walker GC. Error-prone translesion synthesis mediates acquired chemoresistance. Proceedings of the National Academy of Sciences of the United States of America. 107: 20792-7. PMID 21068378 DOI: 10.1073/pnas.1011412107  0.96
2010 Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 107: 20786-91. PMID 21068376 DOI: 10.1073/pnas.1011409107  0.96
2010 Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 143: 355-66. PMID 21029859 DOI: 10.1016/j.cell.2010.09.043  0.96
2010 Doles J, Hemann MT. Nek4 status differentially alters sensitivity to distinct microtubule poisons. Cancer Research. 70: 1033-41. PMID 20103636 DOI: 10.1158/0008-5472.CAN-09-2113  0.96
2009 Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. 16: 324-35. PMID 19800577 DOI: 10.1016/j.ccr.2009.08.015  0.96
2009 Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genetics. 41: 1133-7. PMID 19783987 DOI: 10.1038/ng.451  0.96
2009 Christian Reinhardt H, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle. 8: 3112-3119. PMID 19755856  0.96
2009 Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Molecular Cancer Therapeutics. 8: 2183-92. PMID 19671754 DOI: 10.1158/1535-7163.MCT-08-1203  0.96
2009 Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response Genes and Development. 23: 1895-1909. PMID 19608766 DOI: 10.1101/gad.1815309  0.96
2008 Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 105: 9053-8. PMID 18574145 DOI: 10.1073/pnas.0803513105  0.96
2007 Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science (New York, N.Y.). 315: 1576-9. PMID 17322030 DOI: 10.1126/science.1137999  0.96
2007 Hemann MT, Narita M. Oncogenes and senescence: breaking down in the fast lane. Genes & Development. 21: 1-5. PMID 17210783 DOI: 10.1101/gad.1514207  0.96
2006 Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death and Differentiation. 13: 1256-9. PMID 16710363 DOI: 10.1038/sj.cdd.4401962  0.96
2005 Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genetics. 37: 1289-95. PMID 16200064 DOI: 10.1038/ng1651  0.96
2005 Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 436: 807-11. PMID 16094360 DOI: 10.1038/nature03845  0.96
2005 He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. A microRNA polycistron as a potential human oncogene. Nature. 435: 828-33. PMID 15944707 DOI: 10.1038/nature03552  0.96
2005 Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. Embo Reports. 6: 177-83. PMID 15678160 DOI: 10.1038/sj.embor.7400333  0.96
2005 Hemann MT, Lowe SW. P53 links tumor development to cancer therapy 25 Years of P53 Research. 339-351. DOI: 10.1007/978-1-4020-2922-6_15  0.96
2004 Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 430: 797-802. PMID 15306814 DOI: 10.1038/nature02820  0.96
2004 Chiang YJ, Hemann MT, Hathcock KS, Tessarollo L, Feigenbaum L, Hahn WC, Hodes RJ. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Molecular and Cellular Biology. 24: 7024-31. PMID 15282303 DOI: 10.1128/MCB.24.16.7024-7031.2004  0.96
2004 Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW. Suppression of tumorigenesis by the p53 target PUMA. Proceedings of the National Academy of Sciences of the United States of America. 101: 9333-8. PMID 15192153 DOI: 10.1073/pnas.0403286101  0.96
2003 Rabinowicz PD, Palmer LE, May BP, Hemann MT, Lowe SW, McCombie WR, Martienssen RA. Genes and transposons are differentially methylated in plants, but not in mammals. Genome Research. 13: 2658-64. PMID 14656970 DOI: 10.1101/gr.1784803  0.96
2003 O'Hearn SF, Huang CE, Hemann M, Zhelonkina A, Sollner-Webb B. Trypanosoma brucei RNA editing complex: band II is structurally critical and maintains band V ligase, which is nonessential. Molecular and Cellular Biology. 23: 7909-19. PMID 14560033 DOI: 10.1128/MCB.23.21.7909-7919.2003  0.96
2003 Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Research. 63: 5703-6. PMID 14522887  0.96
2003 Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics. 33: 396-400. PMID 12567186 DOI: 10.1038/ng1091  0.96
2002 Hathcock KS, Hemann MT, Opperman KK, Strong MA, Greider CW, Hodes RJ. Haploinsufficiency of mTR results in defects in telomere elongation. Proceedings of the National Academy of Sciences of the United States of America. 99: 3591-6. PMID 11904421 DOI: 10.1073/pnas.012549799  0.96
2001 Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107: 67-77. PMID 11595186 DOI: 10.1016/S0092-8674(01)00504-9  0.96
2001 Hemann MT, Rudolph KL, Strong MA, DePinho RA, Chin L, Greider CW. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Molecular Biology of the Cell. 12: 2023-30. PMID 11452000  0.96
2001 Rusché LN, Huang CE, Piller KJ, Hemann M, Wirtz E, Sollner-Webb B. The two RNA ligases of the Trypanosoma brucei RNA editing complex: cloning the essential band IV gene and identifying the band V gene. Molecular and Cellular Biology. 21: 979-89. PMID 11158286 DOI: 10.1128/MCB.21.4.979-989.2001  0.96
2000 Hemann MT, Hackett J, IJpma A, Greider CW. Telomere length, telomere-binding proteins, and DNA damage signaling. Cold Spring Harbor Symposia On Quantitative Biology. 65: 275-9. PMID 12760041  0.96
2000 Hemann MT, Greider CW. Wild-derived inbred mouse strains have short telomeres. Nucleic Acids Research. 28: 4474-8. PMID 11071935  0.96
1999 Hemann MT, Greider CW. G-strand overhangs on telomeres in telomerase-deficient mouse cells. Nucleic Acids Research. 27: 3964-9. PMID 10497259 DOI: 10.1093/nar/27.20.3964  0.96
Show low-probability matches.